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A B S T R A C T
The organophosphorus (OP) pesticide malathion is a highly neurotoxic compound and its toxicity is
primarily caused by the inhibition of acetylcholinesterase (AChE), leading to cholinergic syndrome.
Although oximes have been used as potential antidotal treatments in malathion poisoning because of
their potential capability to reactivate the inhibited enzyme, the clinical experience with the clinically
available oximes (e.g. pralidoxime) is disappointing and their routine use has been questioned. In the
present study, we investigated the potency of pralidoxime and K074 in reactivating AChE after acute
exposure to malathion, as well as in preventing malathion-induced changes in oxidative-stress related
parameters in mice. Malathion (1.25 g/kg, s.c.) induced a signiﬁcant decrease in cortico-cerebral,
hippocampal and blood AChE activities at 24 h after exposure. Oxime treatments (1/4 of LD50, i.m., 6 h
after malathion poisoning) showed that pralidoxime signiﬁcantly reversed malathion-induced blood
AChE inhibition, although no signiﬁcant effects were observed after K074 treatment. Interestingly, both
oximes tested were unable to reactivate the cortico-cerebral and hippocampal enzymes after
intramuscular or intracerebroventricular injection (1/4 of LD50, 6 h after malathion poisoning).
Biochemical parameters related to oxidative stress (cerebro-cortical and hippocampal glutathione
peroxidase, glutathione reductase and catalase activities, as well as lipid peroxidation) were not affected
in animals treated with malathion, oximes or atropine alone. However, pralidoxime and K074,
administered intramuscularly 6 h after malathion poisoning, were able to increase the endogenous
activities of these antioxidant enzymes in the prefrontal cortex and hippocampus. Taken together, the
results presented herein showed that pralidoxime (the most common clinically used oxime) and the
recently developed oxime K074, administered 6 h after malathion poisoning, were unable to reactivate
the inhibited AChE in mouse prefrontal cortex and hippocampus. However, only pralidoxime
signiﬁcantly reversed the blood AChE inhibition induced by malathion poisoning. This indicates that
peripheral and central AChE activities are not necessarily correlated after the treatment of OP compounds
and/or oximes, which should be taken into account in the diagnosis and management of OP-exposed
humans. In addition, considering that the available treatments to malathion poisoning appear to be
ineffective, the present study reinforce the need to search for potential new AChE reactivators able to
efﬁciently reactivate the brain and blood AChEs after malathion poisoning.
 2011 Elsevier Inc. 
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Organophosphorus (OP) compounds display a broad variety of
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Open access under the Elsevier OA license.view, they are well-known inhibitors of cholinesterases (ChEs),
leading to the accumulation of acetylcholine in the synaptic
terminals at the central and peripheral nervous systems, causing
the consequent overstimulation of the cholinergic pathways
(Bajgar, 2004; Bartling et al., 2007; Kwong, 2002).
The diagnosis of OP poisoning is based on anamnesis, the
clinical status of the intoxicated organism, and on ChE determina-
tion in the blood (Bajgar, 2004). The measurement of this
peripheral marker (activity of blood ChEs) has been extremely
Fig. 1. Chemical structure of oximes used.
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reports underlining the appropriateness of blood ChE as a
surrogate parameter that mirrors the synaptic enzyme (Eyer
et al., 2007).
Malathion (O,O-dimethyl-S-1,2-bis ethoxy carbonyl ethyl
phosphorodithioate) is an OP compound widely used in agriculture
and veterinary practices as well as in attempts at suicide (Maroni
et al., 2000). Of particular importance, our Toxicological Informa-
tion Centre (Floriano´polis, SC, Brazil) has reported that most of the
cases of OP poisoning attended in our University Hospital were due
to the exposure to malathion. Its toxicity requires the bioactivation
to malaoxon (Buratti et al., 2006; Forsyth and Chambers, 1989),
which is the molecule able to phosphorylate and inactivate ChEs
(Taylor et al., 1995) – mainly acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE). Similarly to others OP compounds,
malathion also leads to cholinergic syndrome (Abou-Donia, 2003;
Brocardo et al., 2005; Franco et al., 2009; Trevisan et al., 2008).
Despite the clear involvement of AChE in the deleterious
symptoms elicited by malathion, other targets and events
potentially involved in its toxicity have been reported (Bajgar
et al., 2007; Brocardo et al., 2005; Ranjbar et al., 2002, 2010; Videira
et al., 2001). Particularly, oxidative damage produced by increased
levels of lipid peroxidation (Akhgari et al., 2003; Ranjbar et al.,
2010) and altered activities of antioxidant enzymes (Akhgari et al.,
2003; Franco et al., 2009; Ranjbar et al., 2010; Trevisan et al., 2008)
has been extensively reported. However, the exact mechanism by
which malathion and others OP compounds induce oxidative
damages is not fully understood.
The standard treatment for OP intoxication usually consists of
the administration of a muscarinic cholinergic receptor antago-
nist (e.g. atropine) in combination with a reactivator containing
an oxime functional group (da Silva et al., 2008; dos Santos et al.,
2010). Anticholinergic drugs block the effects of overstimulation
by accumulated acetylcholine at peripheral muscarinic receptors
while the oximes, as compounds with nucleophilic activity, are
able to break down the bond between the enzyme and the OPs
inhibitors (dephosphorylation), releasing the enzyme to perform
its physiological role (Bartosova et al., 2006; Kassa et al., 2007).
Oximes have been investigated for many years as compounds
with a great potential to the treatment of OPs poisoning (Dawson,
1994), however, the efﬁcacy of commonly used oxime reactivators
is still not sufﬁcient and few compounds have found clinical
application (Antonijevic and Stojiljkovic, 2007; Jokanovic and
Stojiljkovic, 2006).
As the ability of the currently oximes used for the antidotal
treatment of OPs poisoning (e.g. pralidoxime) is not fully
satisfactory, the replacement of commonly used oximes by more
effective molecules has been a long-standing goal (Kassa et al.,
2007). Of particular interest, the antidotal treatment of malathion
poisoning with pralidoxime (the standard oxime used in such
condition) has not been efﬁcient to reactivate inhibited AChE
(Sudakin et al., 2000). In this scenario, there is a clear demand for
new reactivators of malaoxon-inhibited AChE with a higher efﬁcacy
than those clinically available.
A recent study from our group showed that K074, a relatively
new developed oxime that was synthesized at the Department of
Toxicology, Faculty of Military Health Sciences, Hradec Kralove,
Czech Republic, presented an outstanding reactivating effects
toward malaoxon-inhibited mouse brain AChE under in vitro
conditions (dos Santos et al., 2010). It is noteworthy that the
reactivating effect of K074 was signiﬁcantly higher when
compared to that of pralidoxime when both oximes were present
at equimolar concentrations. Based on these evidences, the
present study aimed to investigate the in vivo reactivating effects
of K074 toward AChE of malathion-poisoned mice. Its potential
reactivating effect was compared with the commonly clinicallyused oxime (pralidoxime), whose reactivating efﬁcacy has been
questioned. Although several studies (Kassa et al., 2009) have
explored the efﬁcacy of protective agents against OP poisoning
based on protocols with simultaneous exposures to both OP
compounds and oximes, we performed an intoxication schedule
where the oximes were administered 6 h after the OP (malathion)
treatment. This was done in order to mimic a real condition where
humans (mainly agricultures) spend several hours to reach
emergency health services after an acute poisoning event. The
ability of oximes in reactivating inhibited AChE was evaluated in
the prefrontal cortex, hippocampus and blood of the poisoned
animals. Considering the importance of oxidative stress in the
malathion neurotoxicity, the effectiveness of K074 and pralidox-
ime to counteract this phenomenon was also evaluated in the
prefrontal cortex and hippocampus.
2. Materials and methods
2.1. Chemicals
Commercial-grade malathion (O,O-dimethyl-S-1,2-bis ethoxy
carbonyl ethyl phosphorodithioate, 95% purity, CAS 121–75–5)
was purchased from Dipil Chemical Ind. (Brazil). b-Nicotinamide
adenine dinucleotide phosphate sodium salt reduced from 5,50-
dithio-bis(2-nitrobenzoic) acid, glutathione reductase from baker’s
yeast and reduced glutathione were obtained from Sigma (St.
Louis, MO, USA). Pralidoxime and K074 (see Fig. 1) of 98.5% purity
were synthesized at the Department of Toxicology of the Faculty of
Military Health Sciences in Hradec Kralove (Czech Republic). Their
purity was analyzed using high performance liquid chromatogra-
phy. All other chemicals were of the highest grade available
commercially.
2.2. Animals
Adult Swiss male mice (60 days old), from our own breeding
colony, were maintained at 22 8C, on a 12 h light:12 h dark cycle,
with free access to food and water. All experiments were
conducted in accordance with the Guiding Principles in the Use
of Animals in Toxicology, adopted by the Society of Toxicology
(1989) and were approved by our ethics committee for animal use
at the Universidade Federal de Santa Catarina (PP00060/CEUA;
23080.024292/2006-22/UFSC).
2.3. Treatments
2.3.1. Intramuscular oximes injection
Forty-eight animals were randomly divided into eight groups
(A–H) with 6 animals each. Animals from groups E–H received a
single subcutaneous (s.c.) malathion injection (1.25 g/kg). Animals
from groups D/F–H received a single intraperitoneal (i.p.) atropine
sulfate injection (20 mg/kg, dissolved in saline). The oxime
pralidoxime (66 mg/kg; 1/4 LD50) or K074 (5.8 mg/kg; 1/4 LD50),
dissolved in saline, was administered intramuscularly (i.m.) to
animals from groups B/G and C/H, respectively. LD50 were based on
previous reports (Kassa and Humlicek, 2008; Kassa et al., 2005) and
Fig. 2. Effects of malathion, atropine and oximes treatment on the AChE activity in the
prefrontal cortex (A), hippocampus (B) and blood (C) of mice. Animals were treated
with a single malathion injection (1.25 g/kg, s.c.) and 6 h after the malathion exposure
the oximes were administered (1/4 LD50, i.m.). Enzyme activity in the prefrontal
cortex, hippocampus and blood is expressed as % of control (n = 6 animals per group).
Basal AChE activity was 11.70  2.533 nmol of substrate hydrolyzed/min/mg protein in
the cortex, 5.374  1.176 nmol of substrate hydrolyzed/min/mg protein in the
hippocampus and 1.882  0.7071 mmol of substrate hydrolyzed/min/mg Hb in the
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(i.m.) were administered 6 h after malathion treatment. Malathion
dose was based on a previous study from our group (da Silva et al.,
2008) and this exposure protocol was developed in an attempt to
mimic a real condition of severe human poisoning to malathion,
characterized by high (around 70%) blood AChE inhibition (WHO,
1986). Vehicle (saline) administrations were performed in control
the conditions. Animals from groups D/F–H received a single
intraperitoneal (i.p.) atropine sulfate injection (20 mg/kg, dis-
solved in saline).
2.3.2. Intracerebroventricular oximes injection
Oximes (dissolved in saline) or saline was injected intracer-
ebroventricularly (i.c.v.) 6 h after a single malathion injection
(1.25 g/kg, s.c.). Brieﬂy, a microsyringe with a specially made 28-
gauge stainless steel needle, 3 mm in length, was used for
microinjections. Mice were anaesthetized lightly with ether (just
that necessary for loss of the postural reﬂex) and needle was inserted
unilaterally 1 mm to the right of the midline point equidistant from
each eye and 1 mm posterior to a line drawn through the anterior
base of the eyes (used as external reference). Pralidoxime (300 nmol/
3 ml, 1/4 LD50), K074 (30 nmol/3 ml, 1/4 LD50) or saline was
delivered gradually into the lateral ventricle, at the following
coordinates from bregma: anteroposterior (AP) = 0.1 mm, medio-
lateral (ML) = 1 mm, and dorsoventral (DV) = 2.4 mm. LD50 were
based on a preliminary toxicological study.
2.4. Tissue preparation for biochemical analyses
Twenty-four hours after malathion exposure, animals were
submitted to ether anesthesia and the blood was collected by cardiac
puncture in heparinized tubes. Then, the animals were killed by
decapitation and the prefrontal cortices and hippocampus were
removed and homogenized (1:10 w/v) in HEPES 25 mM, pH 7.4
buffer. The tissue homogenates were centrifuged at 3000  g, at 4 8C
for 5 min and an aliquot was used for the determination of AChE
activity. Thereafter, the supernatants of the ﬁrst centrifugation
were again centrifuged at 16,000  g, at 4 8C for 20 min and the
supernatants obtained were used for the determination of
enzymatic activities (glutathione peroxidase, glutathione reductase
and catalase). For determination of blood AChE activity, whole blood
was diluted (1:25, v:v) in ultrapure water and the hemolyzed sample
was used for the measurement of AChE activity, which were
normalized by hemoglobin (Hb) content. The Hb concentration was
measured at 540 nm as cyano-met-Hb form based on Ventura et al.
(1967) with minor modiﬁcations from Farina et al. (2002).
2.5. Biochemical analyses
2.5.1. Acetylcholinesterase activity
Brain and blood AChE activity was estimated by the method of
Ellman et al. (1961), using acetylthiocholine iodide as a substrate.
The rate of hydrolysis of acetylthiocholine iodide is measured at
412 nm through the release of the thiol compound which, when
reacted with DTNB, produces the color-forming compound TNB.
2.5.2. Antioxidant enzymes
Glutathione peroxidase (GPx) activity was measured by the
Wendel (1981) method, using tert-butylhydroperoxide as a
substrate. NADPH disappearance was monitored by a spectropho-
tometer at 340 nm. Glutathione reductase (GR) activity wasblood (mean  SEM). *p < 0.05, **p < 0.01 and ***p < 0.001 when compared with the
control treated with saline, #p < 0.05 when compared with malathion/atropine-treated
group for the analysis of variance (ANOVA) followed by Duncan multiple range test.
Fig. 3. Effects of malathion, atropine and oximes treatment on mouse prefrontal
cortex glutathione reductase (A), glutathione peroxidase (B) and catalase (C)
activities. Animals were treated with a single malathion injection (1.25 g/kg, s.c.)
and 6 h after the malathion exposure the oximes were administered (1/4 LD50, i.m.).
Glutathione peroxidase (GPx), glutathione reductase (GR) and catalase activities are
expressed as % of control (n = 6 animals per group). Basal enzyme activity was
34.05  3.615 nmol of NADPH oxidized/min/mg protein for GR, 14.58  0.7044 nmol
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(1985). The rate of GSSG reduction was indirectly determined
through monitoring the NADPH disappearance at 340 nm. Catalase
activity was measured by the method of Aebi (1974). The reaction
was started by the addition of freshly prepared 30 mM H2O2. The
rate of H2O2 decomposition was measured spectrophotometrically
at 240 nm.
2.5.3. Determination of protein
The protein content was quantiﬁed by the method of Bradford
(1976), using bovine serum albumin as a standard.
2.6. Statistical analysis
Differences between groups were evaluated by analysis of
variance (ANOVA), followed by Duncan’s multiple range tests
when appropriate (statistical signiﬁcance set at p < 0.05).
3. Results
First of all, we performed toxicological studies with either
pralidoxime or K074 in order to ﬁnd their LD50 in Swiss mice. Based
on the mortality rate at 24 h after single i.m. or i.c.v. injections, we
found LD50 values of approximately 264 and 23.2 mg/kg (i.m.) and
1200 and 120 nmol/site (i.c.v.) for pralidoxime and K074, respec-
tively. Thereafter, we investigated the potential ability of these
oximes (1/4 LD50, i.m., in combination with atropine) in reversing
malathion-induced AChE inhibition in the prefrontal cortex,
hippocampus and blood of mice 24 h after malathion exposure
(Fig. 2). It is important to emphasize that the potential antidotal
treatments were administered 6 h after malathion treatment in
order to mimic a real condition where humans (mainly agricultures)
spend several hours to reach emergency health services after an
acute poisoning event. One-way ANOVA showed signiﬁcant effects
of treatments on cortico-cerebral [F(7, 41) = 12.97; P < 0.001]
(Fig. 2A), hippocampal [F(7, 45) = 19.72; P < 0.001] (Fig. 2B) and
blood [F(7, 42) = 8.86; P < 0.001] (Fig. 2C) AChE activity. Malathion
exposure signiﬁcantly (P < 0.001) inhibited the AChE activity in the
prefrontal cortex (around 50%), hippocampus (around 40%) and
blood (around 70%). Pralidoxime or K074 (in combination with
atropine) were unable to reverse malathion-induced AChE inhibi-
tion in the prefrontal cortex and hippocampus 18 h after oximes
injection (Fig. 2A and B). Only pralidoxime (43%, P < 0.05)
signiﬁcantly reversed (although partially) the AChE inhibition
induced by malathion poisoning in the blood (Fig. 2C).
Since oxidative stress has been proposed as an important
mechanism involved with malathion-induced neurotoxicity, we
investigated the effects of malathion and oximes exposures on
biochemical parameters related to the antioxidant defenses
(glutathione peroxidase, glutathione reductase and catalase) and
thiobarbituric acid reactive substances (TBARS, marker of lipid
peroxidation) in the prefrontal cortex and hippocampus (Figs. 3 and
4). This was performed in order to investigate whether the oximes
(administered intramuscularly) could prevent the occurrence of
malathion-induced changes on oxidative stress-related parameters
in these encephalic structures, correlating these possible preventive
effects with potential reactivating events. Fig. 3 shows the effects of
malathion (s.c.) and oximes (i.m.) exposures on the activities of
antioxidant enzymes from prefrontal cortex. The treatments with
malathion, atropine, pralidoxime or K074 alone did not affectof NADPH oxidized/min/mg protein for GPx and 0.7846  0.1613 mmol of substrate
hydrolyzed/min/mg protein for catalase (mean  SEM). *p < 0.05, **p < 0.01 and
***p < 0.001 when compared with the control treated with saline by analysis of
variance (ANOVA) followed by Duncan multiple range test.
Fig. 4. Effects of malathion, atropine and oximes treatment on hippocampal
glutathione reductase (A), glutathione peroxidase (B) and catalase (C) activities.
Animals were treated with a single malathion injection (1.25 g/kg, s.c.) and 6 h after
the malathion exposure the oximes were administered (1/4 LD50, i.m.). Glutathione
peroxidase (GPx), glutathione reductase (GR) and catalase activities are expressed as %
of control (n = 6 animals per group). Basal enzyme activity was 38.29  1.498 nmol of
NADPH oxidized/min/mg protein for GR, 11.71  0.9502 nmol of NADPH oxidized/min/
mg protein for GPx and 0.7620  0.1213 mmol of substrate hydrolyzed/min/mg protein
for catalase (mean  SEM). *p < 0.05, **p < 0.01 and ***p < 0.001 when compared with
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ties in the prefrontal cortex 24 h after administrations (Fig. 3).
However, glutathione peroxidase (P < 0.001), glutathione reductase
(P < 0.001) and catalase (P < 0.001) activities were signiﬁcantly
increased when pralidoxime was injected 6 h after the malathion
poisoning, when compared with the control group. Moreover, the
oxime K074 signiﬁcantly increased glutathione peroxidase
(P < 0.05) and glutathione reductase (P < 0.01) activities in the
prefrontal cortex (Fig. 3A and B). Fig. 4 shows the effects of malathion
and oximes exposure on the hippocampal activities of antioxidant
enzymes. Similarly to the prefrontal cortex, the treatment with
malathion, atropine, pralidoxime and K074 alone did not affect
glutathione peroxidase, glutathione reductase and catalase activi-
ties in the hippocampus 24 h after treatments. However, both
oximes signiﬁcantly increased the glutathione reductase activity
when injected 6 h after malathion poisoning [Fig. 4A; P < 0.01
(pralidoxime) and P < 0.001 (K074)]. Pralidoxime, but not K074, was
able to increase glutathione peroxidase activity in the hippocampus
(Fig. 4B; P < 0.05) when compared to the control group, as well as
increase catalase activity in the hippocampus when compared to the
malathion + atropine group (Fig. 4C; P < 0.05).
Although the intramuscular treatments with pralidoxime and
K074 were able to increase the activities of antioxidant enzymes in
the prefrontal cortex and hippocampus of malathion-treated
animals, biochemical parameter related to the lipid peroxidation
(TBARS) was not changed in these structures by treatments (data
not shown).
Taking into account that the absence of signiﬁcant reactivating
effects of either pralidoxime or K074 toward hippocampal and
cortical AChE (Fig. 2) could be due to the limited transport of both
oximes through the blood–brain barrier (Bajgar et al., 2007; Lorke
et al., 2007; Sakurada et al., 2003), a further experiment based on
i.c.v. oxime administration was performed. As expected, malathion
exposure signiﬁcantly (P < 0.01) inhibited the AChE activity in the
prefrontal cortex and hippocampus (around 50%) at 24 h after a
single administration. The i.c.v. injections of pralidoxime or K074,
which were performed at 6 h after malathion poisoning, were
unable to reverse malathion-induced AChE inhibition in the
prefrontal cortex and hippocampus (Fig. 5A and B).
4. Discussion
Organophosphorus (OP) compounds are highly toxic agents
that represent the largest class of insecticides sold worldwide.
They are widely and effectively used in agriculture, and to a lesser
extent, in domestic pest control (Jaga and Dharmani, 2003;
Kamanyire and Karalliedde, 2004). Particularly important, data
published by our Toxicological Information Center shows that
malathion, a well-known OP compound, is featured on the record
of human intoxications in Santa Catarina, a state in Southern Brazil.
The toxic effects elicited by acute malathion poisoning are
mainly attributed to the inhibition of AChE in the nervous tissue,
leading to increased acetylcholine levels in the synaptic cleft and
causing cholinergic syndrome (Kwong, 2002). The standard clinical
treatment for malathion poisoning, which represents the combi-
nation of anticholinergic drugs (atropine) and AChE reactivators
(oximes), is not sufﬁciently effective (Sudakin et al., 2000). Of
particular importance, the lack of brain penetration is a major
limitation for the currently used oximes as antidotes of OP
poisoning (Kalisiak et al., 2011). Accordingly, pralidoxime, a widely
used oxime in OP poisoning, seems to be a poor reactivator of
OP-inhibited AChE (Kuca et al., 2010) and there are biochemicalthe control treated with saline, #p < 0.05 when compared with malathion/atropine-
treated group by analysis of variance (ANOVA) followed by Duncan multiple range test.
Fig. 5. Effects of malathion and oximes treatment on the AChE activity in the
prefrontal cortex (A) and hippocampus (B) of mice. Animals were treated with a
single malathion injection (1.25 g/kg, s.c.) and 6 h after the malathion exposure the
oximes were administered (1/4 LD50, i.c.v.). Enzyme activity in the prefrontal cortex
and hippocampus is expressed as nmol of substrate hydrolyzed/min/mg protein
and represented as mean  SEM (n = 5 animals per group). *p < 0.05, **p < 0.01 and
***p < 0.001 when compared with the control treated with saline for the analysis of
variance (ANOVA) followed by Duncan multiple range test.
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inhibited by malathion exposure (Ganendran and Balabaskaran,
1976). Nevertheless, pralidoxime has been commercially available
for many years and it is still considered as a gold standard of AChE
reactivators (Kuca et al., 2010). From a clinical point of view, there
is a clear demand for more effective reactivators of malathion-
inhibited AChE to efﬁciently alleviate the neurotoxic symptoms.
Previous studies from our group have demonstrated that
oximes from the K-series (developed by Kuca from Department of
Toxicology of the Faculty of Military Health Sciences, Hradec
Kralove, Czech Republic) namely K027, K048, K074 and K075 are
potent reactivators of AChE inhibited by malathion/malaoxon
under in vivo and in vitro conditions (da Silva et al., 2008; dos
Santos et al., 2010). Our previous in vitro study showed that the
oxime K074 presented an outstanding reactivating effect toward
malaoxon-inhibited mouse brain AChE, which was signiﬁcantly
higher when compared to that of pralidoxime when both oximes
were present at equimolar concentrations (dos Santos et al., 2010).
However, in this in vivo study, efﬁcacy comparisons using
equimolar doses of the tested oximes were not performed because
of their different in vivo toxicities. Based on literature data and on
previous toxicity studies developed in our laboratory, we observed
that the toxicities of standard oximes studied in rodents are HI-
6 < pralidoxime < obidoxime < trimedoxime (Calic et al., 2006;Musilek et al., 2007). Regarding to the oximes from K-series, their
toxicities are K027 < K048 < K075 < K074 (Musilek et al., 2007).
Taking this into consideration, in this study we used 1/4 LD50 for
both oximes and the results showed that pralidoxime and K074
(intramuscularly administered) were not able to reactivate the
inhibited AChE in prefrontal cortex and hippocampus of mice at
least within the ﬁrst 24 h after malathion exposure. In contrast,
pralidoxime, but not K074, signiﬁcantly reversed (although
partially) the AChE inhibition induced by malathion poisoning
in the whole blood. These results are in agreement with recent
studies in guinea pigs where oximes (e.g. pralidoxime) exhibited
differential potency in reactivating nerve agent-inhibited choli-
nesterases (ChE) in various peripheral tissues and blood, but did
not affect ChE activity in brain regions (Shih et al., 2009, 2010).
These data are particularly important taking into consideration the
use of blood AChE as an important parameter to predict the
inhibition status of the synaptic enzyme (Eyer et al., 2007). The
data suggest that peripheral and central AChE activities are not
necessarily correlated after the treatment of OP compounds and/or
oximes, which should be taken into account in the diagnosis and
management of OP-exposed humans.
The effectiveness of oxime-mediated reactivation is primarily
attributed to the nucleophilic displacement rate of organopho-
sphates, but the reactivating efﬁciency varies with the chemical
structure of the OP compound, the source of enzyme, the chemical
structure of the oxime and the rate of postinhibitory dealkylation,
known as aging (Kovarik et al., 2004; Worek et al., 2002). In the
present study, the reactivating effects of pralidoxime were relatively
low when compared to their high reactivating effects toward
malaoxon-inhibited AChE under in vitro conditions (dos Santos et al.,
2010). In fact, the results of the present study showed no signiﬁcant
reactivating effects of both oximes toward cortico-cerebral and
hippocampus AChE. Moreover, a modest (although signiﬁcant)
reactivating effect of pralidoxime was observed toward blood AChE.
These events should be related, at least in part, to the rate of
postinhibitory dealkylation (aging), which may be a consequence of
the exposure schedule. In fact, the administration of the oximes at
6 h after malathion poisoning likely allows for the occurrence of high
levels of dealkylation in the enzyme–inhibitor complex, decreasing
the probability of reactivation by oximes. This experimental
evidence is in agreement with the lack of satisfactory reactivating
effects of oximes in malathion poisoning, suggesting that the rate
of AChE aging in malathion poisoning is high. From a clinical point
of view, it is important to emphasize that our exposure protocol
was performed in an attempt to mimic real conditions, in which
humans (mainly rural workers) poisoned by malathion do not
achieve immediate health care after acute intoxication.
Kinetic parameters certainly may affect the inhibitory efﬁcacy
of OP compounds, as well as the reactivating effects of oximes. In
this regard, high bioavailabilities of OP compounds and oximes
and their distributions through the blood–brain barrier (BBB)
should be crucial for the reactivation of the brain enzyme. The
transport of pralidoxime, as well as other positively charged
hydrophilic small oximes (obidoxime, K027 and K048) through
the BBB is only minimal (Bajgar et al., 2007; Lorke et al., 2007;
Sakurada et al., 2003). Sakurada et al. (2003) have reported that
the mean BBB penetration of pralidoxime is approximately 10%. In
addition, it was suggested that the ratio of brain extracellular
ﬂuid to blood concentration of pralidoxime would be lower after
OP poisoning because pralidoxime is used for reactivation of
inhibited AChE in blood prior to BBB penetration (Sakurada et al.,
2003). It is important to emphasize here that the ability of the
oxime K074 in crossing the BBB has not been well described in
literature. However, in this study, the absence of reactivating
effects toward brain AChE suggests that K074 may have limited
access to the CNS.
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effectively cross the BBB, a protocol of i.c.v. administrations was
performed. However, even after i.c.v. injection, pralidoxime or
K074 were unable to reverse malathion-induced AChE inhibition in
the prefrontal cortex and hippocampus. These results indicate that
both oximes, which were intracerebroventricularly injected at
high levels (1/4 LD50), were unable to destabilize the complex
formed between hippocampal/cortical AChE and malaoxon, at
least when administered 6 h after malathion exposure. The data
suggest that the rate of postinhibitory dealkylation (aging)
represents a crucial event in the CNS, which should be taken into
account when using oximes to treat malathion poisoning. In
agreement with this idea, our data showed that i.m. pralidoxime
administration signiﬁcantly reversed malathion-inhibited blood
AChE, but i.c.v. pralidoxime administration did not change the
activity of malathion-inhibited hippocampal and cortical AChE
activity, suggesting that AChE aging seems to depend on the tissue
source (blood vs. CNS). Although literature data on this theme are
scarce, Sket and Brzin (1986) investigated the rate of aging of
soman-inhibited brain AChE and showed a statistically signiﬁcant
reactivation of inhibited AChE in brain only when the oxime (i.c.v.
injected) was applied up to 20 min after soman. Then, it is possible
that an effective reactivating effect with pralidoxime and K074
could be achieved in our model of malathion poisoning if these
oximes were administered immediately after the malathion
exposure. However, additional kinetic studies are necessary to
investigate this hypothesis.
There is evidence for an important role of oxidative stress in the
toxicity elicited by OP agents. Recent studies have shown that
malathion exposure induces oxidative stress in different animal
models by increased lipid peroxidation levels (TBARS) in mouse
and rat brain (Brocardo et al., 2007; da Silva et al., 2008), altered
activities of the antioxidant enzymes glutathione peroxidase
(GPx), glutathione reductase (GR), superoxide dismutase and
catalase (Fortunato et al., 2006), as well as DNA damage in brain
structures after short-term (Brocardo et al., 2007) and chronic
treatment with malathion (Reus et al., 2008). However, the exact
mechanism involved in this phenomenon is not fully understood.
In our experiments, no changes were observed in enzymatic
antioxidant defenses (GR, GPx and catalase activities) and TBARS
levels in prefrontal cortex and hippocampus 24 h after the
malathion exposure. Other results are in agreement with these
data, such as those reported by Acker et al. (2009), which have
shown that the exposure to malathion in rats did not alter
parameters of oxidative stress, such as TBARS levels and non-
enzymatic and enzymatic antioxidant defenses.
Despite the oximes are compounds generally used to reverse
the AChE inhibition caused by OPs (Worek et al., 2004), studies
have proposed that cholinesterase reactivators with antioxidant
properties may be a good approach for OP intoxication treatments
(Puntel et al., 2008, 2009). In a previous study from our group, we
showed that the oximes from K-series, K027 and K048 were able to
reduce the lipid peroxidation in the prefrontal cortex of mice (da
Silva et al., 2008). Additionally, some oximes were able to decrease
TBARS production in brain homogenates induced by malonate and
iron (Puntel et al., 2008) and also exhibited a protective role during
in vitro Cu2+-induced LDL and serum oxidation (de Lima Portella
et al., 2008). In earlier experiments, we measured the hydroxyl
scavenging activity of the pralidoxime and K074 using an in vitro
DPPH assay. The direct interaction between oxime and radical
DPPH was analyzed and the results showed that pralidoxime and
K074 were not able to act against the reactive species DPPH,
showing no antioxidant activity in this assay. Interestingly, in the
present study, the treatments with pralidoxime and K074 alone
were not able to increase the endogenous activities of antioxidant
enzymes in the prefrontal cortex and hippocampus 18 h afteroximes injection. However, the activity of these enzymes was
signiﬁcantly increased when the oximes were administered after
malathion poisoning. From a molecular point of view, it is difﬁcult
clearly to explain these results only based in our results. In
addition, studies about this theme are absent. Thus, additional
studies need to be performed in an attempt to elucidate this
phenomenon.
In conclusion, the present study showed that the oxime K074
and the commonly used oxime pralidoxime were not able to
reactivate inhibited AChE in mouse prefrontal cortex and
hippocampus when administered 6 h after malathion exposure.
However, in the blood, pralidoxime signiﬁcantly reversed the AChE
inhibition induced by malathion poisoning. Moreover, i.c.v.
administration of both oximes (6 h after malathion poisoning)
did not change the inhibitory effect elicited by this OP compound
on hippocampal and cortical AChE activity. Altogether, the results
indicate that: (i) peripheral (blood) and central (hippocampal and
cerebro-cortical) AChE activities are not necessarily correlated
after OP exposure and/or oxime treatment; (ii) the rate of
postinhibitory dealkylation (aging) represents a crucial event in
the CNS, which seems to be kinetically different when compared to
peripheral tissues. These events should be taken into account in the
diagnosis and management of OP-exposed humans. In addition,
because AChE is a key target concerning the toxic effects elicited by
OP compounds and considering that the available treatments
(based on oximes, especially pralidoxime) to malathion poisoning
appear to be ineffective, the present study reinforce the need to
search for potential new AChE reactivators able to efﬁciently
reactivate the brain and blood AChEs after malathion poisoning.
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